{"entity":{"id":"triumvira-immunologics","kind":"company","name":"Triumvira Immunologics","aka":["Triumvira Immunologics, Inc."],"tldr":"Triumvira Immunologics is a Texas and Ontario cell-therapy company whose T-cell antigen coupler (TAC) engages the natural T-cell receptor rather than a CAR; TAC01-CLDN18.2 targets stomach and pancreatic cancers.","summary":"Triumvira Immunologics, with operations in Austin and Hamilton, Ontario, develops T-cell antigen coupler therapies in which an antigen-binding domain is coupled to the endogenous T-cell receptor complex, aiming for the potency of CAR-T with less toxicity. TAC01-HER2 was its first solid tumour programme and TAC01-CLDN18.2 targets Claudin 18.2 in gastric, gastro-oesophageal junction and pancreatic cancers in a phase 1/2 trial.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.triumvira.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["tac01-cldn18-2"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Austin, Texas","country":"US","companyType":"cell-therapy","website":"https://www.triumvira.com/","investors":[],"funding":[]},"route":"/companies/triumvira-immunologics/","neighbours":{"drug":[{"id":"tac01-cldn18-2","kind":"drug","name":"TAC01-CLDN18.2","route":"/drugs/tac01-cldn18-2/"}]}}